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Cyclodextrin-scaﬀolded amphiphilic
aminoglucoside clusters: self-assembling
and gene delivery capabilities†
Eva M. Aguilar Moncayo,a Nicolas Guilloteau,b Ce´line Bienvenu,b
Jose´ L. Jime´nez Blanco,*a Christophe Di Giorgio,*b Pierre Vierling,b
Juan M. Benito,c Carmen Ortiz Melleta and Jose´ M. Garcı´a Ferna´ndezc
Precise control over the architecture of gene carriers is instrumental to manipulate gene delivery eﬃciency.
Combining cationic centers and carbohydrate motifs into monodisperse architectures has been proposed as
a suitable strategy to impart nucleic acid condensation abilities while preserving biocompatibility. Herein, we
have assessed the influence of the arrangement and orientation of cationic elements on the self-assembling
and gene transfer capabilities of polycationic glycoamphiphilic cyclodextrins (pGaCDs). For such purposes, a
series of cyclodextrin multiconjugates bearing aminoglucoside motifs at their primary rim and hexanoyl
chains at the secondary positions were synthesized. In the presence of pDNA, pGaCDs self-assemble into
nanoaggregates that promote cellular uptake and gene expression in COS-7 cells with eﬃciencies that are
intimately associated with the arrangement of amino functionalities imposed by the aminoglucoside
antennae onto the cyclodextrin-scaﬀolded cluster. Although transfection eﬃciencies were lower than those
observed for polyethyleneimine (PEI)-based polyplexes and previously-reported polycationic amphiphilic
cyclodextrins (paCDs), the results reported herein illustrate (i) the dramatic influence that subtle architectural
modifications exert on the supramolecular organization of pGaCDs and (ii) the virtues of monodisperse
systems for tailoring gene transfer capabilities.
Introduction
Gene therapy, involving the introduction and expression of
foreign gene material into cells, bears great promise to cure a
wide range of genetic as well as acquired diseases.1,2 Its eﬀective
development critically depends on the design of appropriate
delivery systems to carry out compaction, protection, cell inter-
nalization and timely release of the gene payload. Viral vectors
have been proven to be highly eﬃcient gene delivery agents.
However, despite success,3 this approach is seriously limited
due to immunogenicity and toxicity risks.4 Alternatively, research
on synthetic gene delivery systems has gained momentum. Non-
viral gene vectors, e.g. cationic polymers or lipids,5 bear impor-
tant safety advantages over viral approaches,6,7 as well as lower
cost and the ease of production. They also oﬀer alternative
mechanisms for gene material delivery, eventually resulting
in improved pharmacokinetics and pharmacodynamics.8,9 The
overall positive surface electrostatic potential of the corre-
sponding complexes with nucleic acids (polyplexes or lipoplexes)
promotes adhesion to negatively charged proteoglycans on the
outer face of the cell membrane, thus facilitating cellular uptake
and transfection.10,11 Yet, the application of non-viral vectors to
humans has been, with remarkable exceptions,12,13 held back by
their poorer delivery eﬃciency.
Lessons learned from the vast amount of research on non-viral
gene carriers highlight the dramatic influence that minute archi-
tectural modifications exert on nucleic acid complex formation
and, consequently, on nanoparticle traﬃcking, cellular uptake,
payload release and gene expression.14–16 However, the inherent
polydispersity and random conformations of many of these
formulations turn into a hurdle to assess structure–activity rela-
tionships (SAR) and optimize carrier performance. Alternatively,
discrete molecular frameworks, allowing the installation of
spatially segregated functional elements, have emerged as an
appealing option.17 Thus, multifunctional pre-organized plat-
forms, such as calixarenes,18 fullerenes,19 pillar[5]arenes,20 and
cyclodextrins (CDs),21–23 have recently been exploited as scaf-
folds to build up monodisperse architectures with the ability to
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condense DNA into transfectious nanoparticles. Among them,
CD-based vectors have been so far the most profusely investi-
gated due to the inherent biocompatibility and the ease of
chemical tailoring of the cyclooligosaccharide core.24,25
In the framework of a project aimed at engineering site-
specific gene vectors,26 we recently observed that installation of
glycosyl antennae onto polycationic amphiphilic CDs (paCDs)
did not only serve to mediate binding to specific receptors
(lectins) on the target cells,27,28 but also dramatically influ-
enced self-assembling capabilities in the presence of nucleic
acids. It can be expected that DNA complexation by polycationic
glycoamphiphilic CDs (pGaCDs) bearing aminoglycoside motifs
will be particularly sensitive to structural modifications. Actually,
the diﬀerential binding of aminoglycoside antibiotics to nucleic
acids has already been exploited in the design of cationic lipid-
type vectors.29–31 Moreover, a number of glycosylated gene
carriers have been shown to operate with transfection efficien-
cies that correlated with their glyco-dependent self-assembling
capabilities in the presence of nucleic acids rather than with
specific recognition events towards target protein receptors.32
To gain a deeper insight into the structural features governing
gene delivery efficiency of pGaCDs, herein we report the synthesis
of a series of representatives featuring different aminoglucoside
motifs, and the assessment of (i) their self-assembling ability
in the presence of pDNA and (ii) the transfection efficiency of
the resulting pGaCD–pDNA nanoaggregates (CDplexes) towards
COS-7 cells. The results indicate that subtle variations in the
topology of the cationic elements significantly impact the stability
and physicochemical properties of the corresponding glycoCD-
plexes and, consequently, cell transfection efficiency and cytotoxi-
city profiles.
Results and discussion
Design criteria and synthesis
It has been previously shown that the number and arrangement
of the cationic elements in paCDs critically influence gene
carrier capabilities.33–36 To pinpoint these effects in the pGaCD
series, three aminoglucosylated bCD derivatives 2–4 (Fig. 1),
featuring subtle differences in the disposition of the cationic
elements but rather similar hydrophobic/hydrophilic balances,
have been now considered. pGaCDs 2–4 also share the same
spacer arm linking the aminoglucoside motif with the CD core.
The thiourea functionalities have been purposely included in
the molecular design since their presence has been previously
shown to be beneficial for promoting reversible nucleic acid
complexation through hydrogen bonding.37 Moreover, the
thiourea-forming reaction has been proven to be extremely
useful in ‘‘click-type’’ multiconjugation schemes.38,39 The pDNA
complexing capabilities and transfection efficiencies of 2–4 have
been evaluated in comparison with paCD 1, one of the most
efficient cyclodextrin-based vector candidates reported to date.33
For the preparation of the diﬀerently-substituted pGaCDs
2–4 a convergent synthetic scheme was designed in which the
key step is the coupling reaction of the heptaisothiocyanate 1733
with a complementary amine-armed glycoconjugate (Scheme 1).
For such purposes, the required isothiocyanates 5–7 were synthe-
sized from the corresponding azidoglucosylenamine derivative
following a previously described methodology.27,40 Isothiocya-
nate derivatives 5–7 were first coupled with N-tritylethylene-1,2-
diamine41 (- 8–10), followed by sequential acetyl (- 11–13) and
trityl cleavage to yield amines 14–16 (71–40% over three steps,
Scheme 1). Triethylamine-promoted nucleophilic addition of the
resulting amine-armed aminoglucoside derivatives 14–16 to
heptaisothiocyanate 1733 in DMF proceeds slowly at room tem-
perature to furnish the fully substituted bCD adducts 18–20.
Final acid-promoted carbamate hydrolysis yielded the target
heptavalent aminoglycoclusters 2–4, which were characterized
as the corresponding perhydrochlorides (71–50% overall,
Scheme 1). The structure and molecular homogeneity of the
CD-centred glycoclusters 18–20 and 2–4 were confirmed by
NMR, MS and combustion analysis, the ensemble of data being
consistent with the expected C7-symmetry arrangement for
homogeneously substituted bCD derivatives.
Assessment of the self-assembling capabilities of pGaCDs 2–4
The tendency of paCDs to form mixed nanoparticles upon
formulation with nucleic acids (CDplexes) is a prerequisite to
achieve eﬃcient intracellular delivery and gene expression.25
The ability of pGaCDs 2–4 to form stable glycoCDplexes was
first assessed by agarose gel electrophoresis at different nitro-
gen/phosphorous (N/P) ratios.42 Uncomplexed pDNA was used
as a control. In order to avoid premature self-aggregation,
Fig. 1 Structure of paCD 1 and pGaCDs 2–4.
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pGaCD stock solutions were prepared using DMSO and further
diluted using the pDNA solution in HEPES buffer (final DMSO
content never exceeded 1% v/v, see Experimental section for
details). All pGaCDs 2–4 retained the characteristic aggregation
tendency of paCDs such as 1 in the presence of nucleic acids,
though with remarkable differences. 6-Aminoglucosylated deri-
vative 2 fully inhibited pDNA migration and prevented ethi-
dium bromide intercalation at N/P Z 5, indicating that pDNA
in the complex is fully protected from the external environment
under these conditions (Fig. 2A), paralleling that reported for
paCD 1.33 On the other hand, its 3-aminoglucosylated congener
4 efficiently retarded pDNA migration but did not fully protect
it from intercalation at the same N/P ratios, indicating that
the plasmid is, at least, partially accessible (Fig. 2B). Finally, the
14-cationic derivative 3 exhibited a significantly larger tendency
to self-aggregate upon dilution into the buffer solution, as seen
by the appearance of a precipitate, thus preventing electro-
phoretic analysis.
The physicochemical properties of pGaCD:pDNA complexes
formulated with 2–4 at N/P 10 were further characterized by
dynamic light scattering (DLS). Table 1 collects the corre-
sponding nanoparticle average diameters and x-potentials.
Both heptacationic pGaCDs 2 and 4 produced CDplexes slightly
larger (about 100 nm) andmore heavily charged (+48 and +54mV)
than those reported for paCD 1 (76 nm and +46 mV, respec-
tively),33 but still in the range of interest for gene delivery (about
100 nm). Attempts to prepare the corresponding glycoCDplexes
from the diaminoglucoside-coated pGaCD 3 failed, however.
As previously observed during the electrophoretic experiments,
turbidity was immediately observed after addition of the aqueous
buffer. DLS measurements revealed the presence of relatively
large aggregates with a high polydispersity index and negative
x-potential (12.0 mV). These results suggest that the larger
tendency to self-aggregate 3 prevents its hierarchical arrangement
around pDNA, irreversibly rendering polydisperse particles. An
appropriate hydrophobic/hydrophilic balance seems to be there-
fore critical in order to trigger reversible interactions with pDNA
leading to a well-ordered self-assembly.
The morphology of the glycoCDplexes was next evaluated by
transmission electron microscopy (TEM). The corresponding
micrographs confirmed the small size and homogeneous distri-
bution of the nanoparticles obtained from pGaCDs 2 and 4
Scheme 1 Synthesis of pGaCDs 2–4.
Fig. 2 Agarose gel electrophoresis shift assay of pGaCDs 2 (panel A) and 4
(panel B) at diﬀerent N/P ratios. Naked pDNA (right lanes in each panel) is
used for comparative purposes.
Table 1 Size (av. hydrodynamic diameter, nm), polydispersity index (P. I.)
and x-potential (mV) of CDplexes of paCDs 1–4 and pDNA formulated at
N/P 10 determined by DLS and M3-PALS analysis, respectively, in the
absence and in the presence of serum
Complex Av. size (nm) P. I. x-potential (mV)
1:pDNA 76  1 0.12 +46  1
1:pDNAa 160  15 0.13 n.d.
2:pDNA 100  20 0.16 +48  1
2:pDNAa 240  20 0.20 n.d.
3:pDNA 260  100 0.50 12  1
4:pDNA 105  7 0.17 +54  2
4:pDNAa 270  25 0.22 n.d.
a Measurements in the presence of serum (10%).
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(Fig. 3). A snail-like ultra-thin structure alternating dark (high
electron density) and light (low electron density) regions could
be observed in some cases, suggesting the arrangement of the
pGaCD molecules in bilayers in the confined space between
pDNA segments. A similar topography has been previously
observed for transfectious CDplexes.27,33 As expected, formula-
tions with derivative 3 did not render well-defined particles, but
rather polydisperse aggregates.
In vitro pDNA transfection into COS-7 cells
The transfection eﬃciency of the self-assembled pGaCD:pDNA
nanocomplexes formulated with 2 and 4 at N/P 5 and 10 was
evaluated using a luciferase-encoding reporter gene (pTG11236,
pCMV-SV40-luciferase-SV40pA) in monkey fibroblast-like COS-7
cells in HEPES buﬀer (20 mM, pH 7.4, see Experimental section
for details) both in the absence and in the presence of serum.
Linear Jet-PEI (22 kDa, polyplexes formulated at N/P 10) as well
as paCD 1 (CDplexes formulated at N/P 5 and 10) and naked
pDNA were used as positive and negative controls, respectively.
At N/P 5, pGaCDs 2–4 did not improve the expression of
luciferase achieved with naked pDNA, neither in the absence nor
in the presence of serum (Fig. 4). In the absence of serum,
formulations at N/P 10 of the heptacationic pGaCDs 2 and 4
enhanced transfection efficiency by 4 and 2 orders of magnitude,
respectively, implying that the corresponding nanoparticles are
internalized to a significant extent through routes that allow
endosome escape, DNA release and protein expression. Indeed,
previous studies on structurally-related paCDs have shown that
CDplexes are rapidly internalised in cells by several endocytic
routes43 and the reversibility of the paCD–pDNA association.44
Remarkably, the luciferase expression efficiency achieved with
2:pDNA glycoCDplexes is only one order of magnitude lower
than that determined for paCD 1 and Jet-PEI, with a much more
favourable toxicity profile than the latter (Fig. 4, panel C). The
large discrepancies between the performances at N/P 10 of
pGaCDs 2 and 4, featuring similar hydrophilic/hydrophobic
balances (7 protonable amino groups in each glucose antenna
and 14 hexanoyl groups at secondary positions of bCD), reveal
the dramatic influence exerted by the presentation mode of the
protonable amine centers. The presence of the amino group at
the primary position of the glucopyranose moiety probably
favours the accessibility of the charged groups in the polycationic
cluster to phosphate anions in the pDNA skeleton. A similar effect
Fig. 3 TEMmicrograph of (A) 2:pDNA and (B) 4:pDNA glycoCDplexes: the
inset in panel A represents the amplification of the structure of the
particles.
Fig. 4 In vitro transfection eﬃciency (bars) at N/P 5 (dotted bars) and 10
(filled bars) in COS-7 cells for CDplexes formulated with paCD 1 and
pGaCDs 2 and 4 in the absence (panel A) and in the presence (panel B) of
serum (10%). Naked pDNA and Jet-PEI-based polyplexes (formulated at
N/P 10) were used as negative and positive controls, respectively. Cell
viability in the absence (K) and in the presence (’) of serum (10%) is
represented in panel C.
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has been observed in cationic lipids furnished with aminoglyco-
side polar heads.29
The presence of serum (10%) led to a generalized eﬃciency
drop for both pGaCDs 2 and 4 when compared to paCD 1.
Probably, the greater increase in size of the glycoCDplexes
formed using 2 and 4 after interaction with serum proteins is
at the origin of this observation. Indeed, DLS measurements in
serum-containing media (Table 1) support this hypothesis.
Such phenomena probably result in weakening of the inter-
action with cell membrane components, thus limiting the
eﬃcient internalization process of nanoparticles and/or causing
less favourable cellular traﬃcking.
CDplexes formulated with pGaCD 3 were unable to promote
pDNA expression under identical experimental conditions
either in the absence or in the presence of serum. Although
improved pDNA binding has been associated with higher
cationic valencies for cationic CDs,45 our results confirm that
in the case of amphiphilic derivatives architectural features
governing the self-assembling properties exert a much larger
influence on the gene delivery capabilities.33,35,46
Conclusions
In summary, the assessment of the self-assembling and gene
transfer capabilities of this set of polycationic glycoamphiphilic
bCD clusters illustrates the utmost relevance of structure–
activity relationship analyses in the design of non-viral gene
carriers. Small differences in the arrangement and display of
the cationic elements responsible for the initial interaction of
individual molecules with nucleic acid (pDNA) may have strong
consequences in the transfection capabilities of the resulting
nanocomplexes. All three pGaCDs clusters 2–4, similar to the
previously reported non-glycosylated paCD 1, are heavily cationic
discrete species. Yet, while 2 and 4 render homogenous nano-
particles (glycoCDplexes) with cell transfection abilities, pGaCD
3 does not. Moreover, remarkable performance disparities are
found for glycoCDplexes formulated with 2 and 4 in COS-7 cells,
with 2:pDNA glycoCDplexes paralleling the golden standard
Jet-PEI with null cytotoxicity. Altogether the present results
illustrate the usefulness of well-defined molecular vectors for
mapping the structural requirements governing DNA complexa-
tion and delivery. The information thus obtained, in combi-
nation with robust synthetic methodologies, can be put forward
in the optimization of the vector architecture.
Experimental
General methods
All chemicals were obtained from Sigma-Aldrich (Germany)
and Panreac (Spain) and were of analytical grade. No further
purification steps were performed unless indicated. All solvents
were used as obtained from the commercial sources. Optical
rotations were measured at room temperature in 1 cm or 1 dm
tubes on a Jasco P-2000 polarimeter. Ultraviolet-visible (UV)
spectra were recorded in 1 cm tubes on a Beckman DU640 UV
spectrophotometer. Infrared (IR) spectra were recorded on a
Jasco FT/IR 6000-Series spectrophotometer and are reported in
reciprocal centimetres (cm1). 1H (and 13C NMR) spectra
were recorded at 500 (125.7) and 400 (100.6) MHz using Bruker
500 and 400DRX instruments. Satisfactory resolutions were
achieved after heating above 313 K. 1D TOCSY, 2D COSY,
HMQC and HSQC experiments were used to assist in the
assignment of NMR spectra. Thin-layer chromatography (TLC)
was carried out on aluminium sheets coated with silica gel 60G
F254 (E. Merck), with visualization by UV light and by charring
with 10% H2SO4. Column chromatography was carried out on
Silica Gel 60 (E. Merck, 230–400 mesh). FAB mass spectra were
recorded using a Kratos MS-80 RFA instrument. The operating
conditions were as follows: the primary beam consisted of Xe
atoms with a maximum energy of 8 keV; the samples were
dissolved in thioglycerol, and the positive ions were separated
and accelerated over a potential of 7 keV; NaI was added as a
cationizing agent. ESI mass spectra were recorded in the
positive ion mode on a Bruker Esquire 6000 ion-trap mass
spectrometer. Typically, samples were dissolved in appropriate
solvents at low mM concentrations. Samples were introduced by
direct infusion, using a Cole-Palmer syringe at a flow rate of
2 mL min1. Ions were scanned between 300 and 6000 Da
with a scan speed of 13 000 Da s1 at unit resolution using
resonance ejection at the multipole resonance of one-third of
the radio frequency (O = 781.25 kHz). Elemental analyses were
performed at the Instituto de Investigaciones Quimicas (Sevilla,
Spain). paCD 1 was prepared according to the reported proce-
dure.33 The starting materials 2,3,4-tri-O-acetyl-6-N-tert-butoxy-
carbonylamino-3-deoxy-b-D-glucopyranosyl isothiocyanate (5),27
2,4-di-O-acetyl-3,6-di-N-tert-butoxycarbonylamino-3,6-dideoxy-b-
D-glucopyranosyl isothiocyanate (6),40 2,4,6-tri-O-acetyl-3-N-tert-
butoxycarbonylamino-3-deoxy-b-D-glucopyranosyl isothiocyanate
(7),40 N-tritylethylene-1,2-diamine,41 and heptakis[6-deoxy-2,3-di-
O-hexanoyl-6-(2-isothiocyanatoethylthio)]cyclomaltoheptaose (17)33
were prepared as described previously.
Syntheses
N0-(N-Trityl-2-aminoethyl)-N-(2,3,4-tri-O-acetyl-6-tert-butoxy-
carbonylamino-6-deoxy-b-D-glucopyranosyl)thiourea (8). To a
solution of N-tritylethylene-1,2-diamine41 (0.50 g, 1.65 mmol)
in pyridine (20 mL) 5 was added27 (0.49 g, 1.10 mmol) and the
reaction mixture was stirred at rt for 15 min, then concentrated.
The solvent was eliminated and pyridine traces were eliminated
by co-evaporation with toluene. The residue was purified by
column chromatography (1 : 1 EtOAc–petroleum ether). Yield:
0.79 g (96%); Rf = 0.40 (1 : 1 EtOAc–petroleum ether); [a]D = 5.4
(c 1.0, DCM); 1H NMR (500 MHz, CDCl3): d = 9.09 (bs, 2H,
NHCS), 7.41–7.17 (m, 15H, Ph), 6.63 (bs, 1H, NHTr), 5.62 (t, 1H,
J1,NH = J1,2 = 9.0 Hz, H-1), 5.34 (t, 1H, J2,3 = J3,4 = 9.0 Hz, H-3),
4.98 (t, 1H, H-2), 4.80 (bs, 1H, H-4), 4.57 (bs, 1H, NH-6), 3.69
(bs, 1H, H-5), 3.34 (bs, 1H, H-6a), 3.14 (bs, 1H, H-6b), 2.56 (m,
2H, CH2NHCS), 2.44 (m, 2H, CH2NHTr), 2.06, 2.05 (3 s, 9H,
MeCO), 1.41 (s, 9H, CMe3);
13C NMR (100.6 MHz, 313 K, CDCl3):
d = 184.6 (CS), 171.5, 171.0, 169.7 (3 CO ester), 155.7 (CO
carbamate), 145.1–126.9 (Ph), 88.3 (C-1), 79.5 (CMe3), 74.3
NJC Paper
 
View Article Online
5220 | New J. Chem., 2014, 38, 5215--5225 This journal is©The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2014
(C-3), 72.9 (C-5, CPh3), 71.4 (C-2), 69.3 (C-4), 60.3 (C-6), 45.3
(CH2NHCS), 40.8 (CH2NHTr), 28.3 (CMe3), 20.9, 20.6, 20.5
(3 MeCO); ESIMS: m/z 771 [M + Na]+; anal. calcd for
C39H48N4O19S: C, 62.55; H, 6.46; N, 7.48. Found: C, 62.71; H,
6.39; N, 7.33.
N0-(N-Trityl-2-aminoethyl)-N-(2,4-di-O-acetyl-3,6-di-tert-butoxy-
carbonylamino-3,6-dideoxy-b-D-glucopyranosyl)thiourea (9). To a
solution of 640 (0.12 g, 0.24 mmol) in dry pyridine (4 mL), N-trityl-
1,2-ethylenediamine41 (0.11 g, 0.36 mmol, 1.5 eq.) was added and
the reaction mixture was stirred at rt for 1 h. The solvent was
evaporated under reduced pressure and traces of pyridine
were removed by co-evaporation with toluene. The residue
was purified by flash column chromatography (2 : 3 - 1 : 1
EtOAc–petroleum ether) to give 11. Yield: 114 mg (58%);
Rf = 0.66 (1 : 1 EtOAc–petroleum ether); [a]D = 1.17 (c 1.0,
MeOH); UV (MeOH): lmax = 246, 216 nm (emM 10.1, 26.1); IR
(NaCl): nmax = 3350, 2975, 1746, 1224, 1034, 706 cm
1; 1H NMR
(400 MHz, CD3OD, 323 K): d = 7.44 (m, 15H, Ph), 5.72 (d, 1H,
J1,2 = 9.3 Hz, H-1), 4.99 (m, 1H, H-2), 4.89 (m, 1H, H-4), 3.90
(m, 1H, H-3), 3.70 (m, 3H, CH2NHCS, H-5), 3.32 (dd, J6a,6b = 14.6 Hz,
J5,6a = 2.7 Hz, H-6a), 3.15 (dd, J5,6a = 6.0 Hz, H-6b), 2.43 (m, 2H,
CH2NHTr), 2.09, 1.95 (2s, 6H,MeCO), 1.43 (s, 18H, CMe3);
13C NMR
(100.6 MHz, CD3OD, 313 K): d = 186.0 (CS), 172.0, 171.6 (CO ester),
158.1, 157.9 (CO carbamate), 147.2–127.4 (Ph), 84.3 (C-1), 80.5
(2 CMe3), 80.4 (CPh3), 76.9 (C-5), 72.3 (C-2), 71.0 (C-4), 57.1 (C-3),
45.9 (CH2NHCS), 44.6 (CH2NHTr), 42.5 (C-6), 28.8, 28.7 (2 CMe3),
20.8, 20.7 (2 MeCO); FABMS: m/z = 828 ([M + Na]+); anal. calcd
for C42H55N5O9S: C, 62.59; H, 6.88; N, 8.69. Found: C, 62.33; H,
6.61; N, 8.51.
N0-(N-Trityl-2-aminoethyl)-N-(2,4,6-tri-O-acetyl-3-tert-butoxy-
carbonylamino-3-deoxy-b-D-glucopyranosyl)thiourea (10). To a
solution of 740 (0.156 g, 0.35 mmol) in dry pyridine (6.4 mL),
N-trityl-1,2-ethylenediamine41 (0.16 g, 0.53 mmol) was added
and the reaction mixture was stirred at rt for 1 h. The solvent
was eliminated under reduced pressure and traces of pyridine
were removed by co-evaporation with toluene. The residue was
purified by column chromatography (2 : 1 EtOAc–petroleum
ether) to give 10. Yield: 0.27 g (quantitative); Rf = 0.51 (1 : 1
EtOAc–petroleum ether); [a]D = 3.6 (c 1.0, DCM); UV (DCM):
lmax = 255, 226 nm (emM 16.0, 19.5); IR (NaCl): nmax = 3351,
3048, 2977, 1746, 1227, 1037, 741, 708 cm1; 1H NMR (500 MHz,
CD3OD, 323 K): d = 7.46 (m, 15H, Ph), 5.78 (d, 1H, J1,2 = 9.5 Hz,
H-1), 5.01 (bs, 2H, H-2, H-4), 4.25 (dd, 1H, J6a,6b = 12.5 Hz, J5,6a =
5.0 Hz, H-6a), 4.10 (dd, 1H, J5,6b = 6.0 Hz, H-6b), 3.93 (m, 1H,
H-3), 3.86 (m, 1H, H-5), 3.71 (m, 2H, CH2NHCS), 2.38 (m, 2H,
CH2NHTr), 2.06, 2.05, 1.97 (3 s, 9H, MeCO), 1.46 (s, 9H, CMe3);
13C NMR (125.7 MHz, CD3OD, 323 K): d = 186.0 (CS), 172.4,
172.1, 171.5 (CO ester), 157.9 (CO carbamate), 147.3–127.3 (Ph),
84.6 (C-1), 80.6 (CMe3), 79.5 (CPh3), 75.8 (C-5), 72.3 (C-2), 70.2
(C-4), 63.6 (C-6), 57.1 (C-3), 46.0 (CH2NHCS), 44.7 (CH2NHTr),
28.7 (CMe3), 20.7, 20.6 (3 MeCO); FABMS: m/z = 771 ([M + Na]
+);
anal. calcd for C39H48N4O9S: C, 48.97; H, 6.58; N, 8.57. Found: C,
62.41; H, 6.329; N, 7.37.
N0-(N-Trityl-2-aminoethyl)-N-(6-tert-butoxycarbonylamino-6-
deoxy-b-D-glucopyranosyl)thiourea (11). Compound 11 was
quantitatively obtained by treatment of 8 (0.76 g, 1.02 mmol)
with methanolic MeONa (0.5 mol per mol of acetates) in MeOH
(10 mL) at 0 1C followed by neutralization with Amberlite
120 (H+). Yield: 0.64 g; Rf = 0.62 (45 : 5 : 3 EtOAc–EtOH–H2O);
[a]D = 11.2 (c 1.0, MeOH); 1H NMR (400 MHz, MeOD, 313 K):
d = 7.45–7.14 (m, 15H, Ph), 5.22 (bs, 1H, H-1), 3.66 (bs, 2H,
CH2NHCS), 3.48 (bd, 1H, J6a,6b = 13.6 Hz, H-6a), 3.41 (t, 1H,
J2,3 = J3,4 = 9.5 Hz, H-3), 3.33 (ddd, 1H, J4,5 = 9.1 Hz, J5,6b = 7.0 Hz,
J5,6a = 2.7 Hz, H-5), 3.27 (bt, 1H, H-2), 3.15 (m, 1H, H-6b), 3.14
(dd, 1H, H-4), 4.57 (bs, 1H, NH-6), 2.37 (m, 2H, CH2NHTr), 1.40
(s, 9H, CMe3);
13C NMR (100.6 MHz, MeOD, 313 K): d = 185.7
(CS), 158.7 (CO carbamate), 147.3–127.4 (Ph), 85.2 (C-1), 80.4
(CMe3), 78.7 (C-3), 77.7 (C-5), 74.4 (C-2), 72.9 (C-4), 72.2 (CPh3),
46.1 (CH2NHCS), 44.7 (CH2NHTr), 42.9 (C-6), 28.8 (CMe3); ESIMS:
m/z 645 [M + Na]+; anal. calcd for C33H42N4O6S: C, 63.64; H, 6.80;
N, 9.00; found: C, 63.62; H, 6.64; N, 8.78.
N0-(N-Trityl-2-aminoethyl)-N-(3,6-di-tert-butoxycarbonylamino-
3,6-dideoxy-b-D-glucopyranosyl) thiourea (12). Compound 12 was
obtained by treatment of 9 (89 mg, 0.11 mmol) with methanolic
MeONa (0.5 mol per mol of acetates) in MeOH (10 mL) at 0 1C.
The crude product was purified by column chromatography (22 : 1
DCM–MeOH). Yield: 71 mg (89%); Rf = 0.67 (22 : 1 DCM–MeOH);
[a]D = 5.2 (c 1.0, MeOH); UV (MeOH): lmax = 243, 214 nm
(emM 17.4, 42.2); IR (KBr): nmax = 3412, 3063, 2973, 1685, 1250,
1079, 706 cm1; 1H NMR (500 MHz, CD3OD, 313 K): d = 7.36
(m, 15H, Ph), 5.21 (bs 1H, H-1), 3.66 (m, 2H, CH2NHCS), 3.49
(dd, J6a,6b = 13.7 Hz, J5,6a = 2.6 Hz, H-6a), 3.41 (d, J2,3 = J3,4 = 9.5 Hz,
1H, H-3), 3.38 (m, 3H, J4,5 = 9.5 Hz, J5,6b = 6.5 Hz, H-5), 3.34
(m, 1H, J1,2 = 9.5 Hz, H-2), 3.14 (dd, 1H, H-6b), 2.43 (m, 2H,
CH2NHTr) 1.43 (s, 18H, CMe3);
13C NMR (125.7 MHz, CD3OD,
313 K): d = 186.0 (CS), 159.2, 158.6 (CO carbamate), 147.4–127.4
(Ph), 86.3 (C-1), 80.6 (2 CMe3), 79.0 (C-5), 72.8 (C-2), 72.3 (CPh3),
71.3 (C-4), 61.8 (C-3), 46.2 (CH2NHCS), 44.8 (CH2NHTr), 43.2 (C-6),
28.4 (2 CMe3); FABMS: m/z = 745 ([M + Na]
+); anal. calcd for
C38H51N5O7S: C, 63.22; H, 7.12; N, 9.70. Found: C, 62.94; H, 7.00;
N, 9.59.
N0-(N-Trityl-2-aminoethyl)-N-(3-tert-butoxycarbonylamino-3-
deoxy-b-D-glucopyranosyl)thiourea (13). Compound 13 was
obtained by treatment of 10 (0.21 g, 0.28 mmol) with metha-
nolic MeONa (0.5 mol per mol of acetates) in MeOH (3 mL) at
0 1C. The reaction mixture was stirred at rt for 35 min. The
crude product was purified by column chromatography (6 : 1
EtOAc–petroleum ether - EtOAc). Yield: 127 mg (71%); Rf =
0.43 (EtOAc); [a]D = 7.3 (c 1.0, DCM); UV (DCM): lmax = 254,
228 nm (emM 15.3, 18.6); IR (NaCl): nmax = 3329, 3083, 2929,
1676, 1292, 1245, 1168, 1079, 1026, 748, 706 cm1; 1H NMR
(500 MHz, CD3OD, 323 K): d = 7.38 (m, 15H, Ph), 5.23 (bs 1H,
H-1), 3.85 (dd, 1H, J6a,6b = 12.0 Hz, J5,6a = 2.5 Hz, H-6a), 3.67 (bs,
2H, CH2NHCS), 3.66 (dd, 1H, J5,6b = 5.0 Hz, H-6b,), 3.48 (t, 1H,
J2,3 = J3,4 = 10.0 Hz, H-3), 3.44 (ddd, 1H, J4,5 = 10.0 Hz, H-5), 3.38
(t, 1H, H-4), 3.43 (m, 1H, H-2), 2.41 (m, 2H, CH2NHTr), 1.48 (s,
9H, CMe3);
13C NMR (125.7 MHz, CD3OD, 323 K): d = 186 (CS),
159.2, (CO carbamate), 130.2–127.4 (Ph), 86.1 (C-1), 80.5
(CMe3), 80.4 (C-5), 72.8 (C-2), 72.2 (CPh3), 70.0 (C-4), 62.9
(C-6), 61.9 (C-3), 46.3 (CH2NHCS), 44.6 (CH2NHTr), 28.8 (CMe3);
FABMS: m/z = 646 ([M + Na]+); anal. calcd for C33H42N4O6S: C,
63.64; H, 6.80; N, 9.00. Found: C, 63.51; H, 6.67; N, 8.85.
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N0-(2-Aminoethyl)-N-(6-tert-butoxycarbonylamino-6-deoxy-b-
D-glucopyranosyl)thiourea (14). Compound 12 (0.2 g, 0.32 mmol)
was treated with 2% TFA in DCM (8mL) at rt for 4 h. The organic
phase was extracted with water (6  10 mL), and the aqueous
solution was neutralized, freeze-dried and then purified by
column chromatography (10 : 1 : 1 MeCN–H2O–NH4OH). Yield:
88 mg (76%); Rf = 0.08 (10 : 1 : 1 MeCN–H2O–NH4OH); [a]D =
19.2 (c 1.0 in H2O); 1H NMR (400 MHz, D2O, 323 K): d = 5.52
(bs, 1H, H-1), 3.89 (bs, 2H, CH2NHCS), 3.78 (t, 1H, J2,3 = J3,4 =
9.0 Hz, H-3), 3.71 (m, 2H, H-5, H-6a), 3.65 (t, 1H, J1,2 = 9.0 Hz,
H-2), 3.51 (dd, 1H, J3,4 = 9.0 Hz, H-4), 3.43 (dd, 1H, J5,6b = 7.2 Hz,
J6a,6b = 13.6 Hz, H-6b), 3.17 (bt, 2H,
3JH,H = 6.0 Hz, CH2NH2), 1.64
(s, 9H, CMe3);
13C NMR (100.6 MHz, D2O, 323 K): d = 184.7 (CS),
159.4 (CO carbamate), 85.5 (C-1), 82.4 (CMe3), 77.7 (C-3), 77.0
(C-5), 73.2 (C-2), 72.2 (C-4), 45.8 (CH2NHCS), 42.5 (C-6), 40.6
(CH2NH2), 28.9 (CMe3); ESIMS: m/z 381 [M + H
+]; anal. calcd for
C14H28N4O6SH2O: C, 42.20; H, 7.59; N, 14.06; found: C, 41.93; H,
7.24; N, 14.49.
N 0-(2-Aminoethyl)-N-(3,6-di-tert-butoxycarbonylamino-3,6-
dideoxy-b-D-glucopyranosyl)thiourea (15). Compound 12 (69 mg,
95 mmol) was treated with 2% TFA in DCM (3 mL) at rt for 5 h.
The organic phase was extracted with water (6 10 mL), and the
aqueous solution was neutralized (diluted NH4OH) and freeze-
dried to give 15. Yield: 35 mg (77%); Rf = 0.43 (10 : 1 : 1 MeCN–
H2O–NH4OH); [a]D = +1.3 (c 0.8, H2O); UV (H2O): 244 nm
(emM 3.6); IR (KBr): nmax = 3117, 1668, 1202, 1137 cm
1;
1H NMR (500 MHz, 12 : 1 CD3OD–D2O, 323 K): d = 5.34 (bs,
1H, H-1), 3.96 (m, CH2NHCS), 3.55 (dd, 2H, J6a,6b = 14.0 Hz, J5,6a =
2.5 Hz, H-6a), 3.49 (m, 3H, H-2, H-4, H-5), 3.29 (t, 1H, J2,3 = J3,4 =
9.3 Hz, H-3), 3.28 (m, 2H, CH2NH2), 3.19 (dd, 1H, J5,6b = 7.0 Hz,
H-6b), 1.49 (s, 18H, CMe3);
13C NMR (125.7 MHz, 12 : 1 CD3OD–
D2O, 323 K): d = 186.5 (CS), 159.2, 158.7 (CO carbamate), 86.0
(C-1), 80.9 (2 CMe3), 78.7 (C-5), 72.3 (C-2), 71.1 (C-4), 61.3 (C-3),
42.9 (C-6), 42.5 (CH2NHCS), 40.6 (CH2NH2), 28.8 (2 CMe3);
ESIMS: m/z = 479.8 [M + H+]; anal. calcd for C19H37N5O7S: C,
47.58; H, 7.78; N, 14.60. Found: C, 47.20; H, 7.45; N, 14.27.
N0-(2-Aminoethyl)-N-(3-tert-butoxycarbonylamino-3-deoxy-b-
D-glucopyranosyl)thiourea (16). Compound 13 (95 mg, 0.15 mmol)
was treated with DCM–TFA (1%, 4 mL) at rt for 4 h. The
organic phase was extracted with water (6  10 mL), and the
aqueous solution was neutralized (NH4OH aqueous) and
freeze-dried to give 16. Yield: 57 mg (quantitative); Rf = 0.88
(10 : 1 : 1 MeCN–H2O–NH4OH); [a]D = 108.1 (c 1.0, MeOH);
UV (MeOH): 248, 212 nm (emM 10.8, 9.0); IR (KBr): nmax = 3300,
3078, 2971, 1687, 1074, 1032 cm1; 1H NMR (500 MHz,
CD3OD, 323 K): d = 5.23 (bs, 1H, H-1), 3.92 (m, 2H, CH2NHCS),
3.86 (dd, 1H, J6a,6b = 12.0 Hz, J5,6a = 2.5 Hz, H-6a), 3.65 (dd, 1H,
J5,6b = 5.5 Hz, H-6b), 3.46 (t, 1H, J2,3 = J3,4 = 9.5 Hz, H-3), 3.44
(m, 1H, H-5), 3.38 (dd, 1H, J1,2 = 9.5 Hz, H-2), 3.34 (dd, 1H,
J4,5 = 9.5 Hz, H-4), 3.20 (m, 2H, CH2NHTr), 1.45 (s, 9H, CMe3);
13C NMR (125.7 MHz, CD3OD, 323 K): d = 186.7 (CS), 159.3 (CO
carbamate), 85.9 (C-1), 80.5 (CMe3, C-5) 72.7 (C-2), 70.1 (C-4),
63.0 (C-6), 61.8 (C-3), 42.8 (CH2NHCS), 40.9 (CH2NH2), 28.8
(CMe3); ESIMS: m/z = 403 [M + Na
+], 381 (63%, [M + H+]); anal.
calcd for C14H28N4O6S: C, 44.20; H, 7.42; N, 14.73. Found: C,
43.88; H, 7.21; N, 14.52.
Heptakis[2,3-di-O-hexanoyl-6-[2-[N0[-2-[N0-(6-deoxy-6-tert-butoxy-
carbonylamino-b-D-glucopyranosyl)thioureido]ethyl]-thioureido]-
ethylthio]]cyclomaltoheptaose (18). To a solution of 1733 (44 mg,
13.6 mmol) in DCM (1 mL), Et3N (16 mL, 0.11 mmol, 1.1 eq.) and
14 (40 mg, 0.105 mmol, 1.1 eq.) in DMF (2 mL) were added and
the reaction mixture was stirred at rt for 7 days. The solvent
was removed under vacuum and the residue was purified by
column chromatography (70 : 10 : 1 DCM–MeOH–H2O). Yield:
61 mg (76%); Rf = 0.35 (70 : 10 : 1 DCM–MeOH–H2O); [a]D =
+34.0 (c 1.0, MeOH); 1H NMR (500 MHz, DMSO-d6, 343 K):
d = 7.72 (bs, 7H, NH-1Glc), 7.64 (bs, 7H, NH), 7.51 (bs, 7H, NH),
7.39 (bs, 7H, NHCyst), 5.27 (t, 7H, J2,3 = J3,4 = 9.0 Hz, H-3), 5.09
(bs, 7H, H-1), 5.04 (bs, 7H, H-1Glc), 4.76 (bs, 7H, NH-6Glc), 4.73
(dd, 7H, J1,2 = 4.0 Hz, H-2), 4.15 (m, 7H, H-5), 3.90 (t, 7H, J4,5 =
9.0 Hz, H-4), 3.64 (bs, 42H, 2 CH2NHCS, CH2NCyst), 3.38 (ddd,
7H, J6a,6b = 14 Hz, JNH,6a = 6.0 Hz, J5,6a = 3.5 Hz, H-6aGlc), 3.25
(m, 7H, H-5Glc), 3.24 (t, 7H, J2,3 = J3,4 = 9.0 Hz, H-3Glc), 3.22 (m,
7H, H-2Glc), 3.09 (m, 14H, H-6a, H6b), 3.01 (t, 7H, J4,5 = 9.0 Hz,
H-4Glc), 3.00 (dd, 7H, J5,6b = 6.0 Hz, H-6bGlc), 2.80 (bs, 14H,
CH2SCyst), 2.36 (m, 14H, H-2aHex), 2.21 (m, 14H, H-2bHex), 1.54
(m, 28H, H-3Hex), 1.39 (s, 63H, CMe3), 1.29 (m, 56H, H-4Hex,
H-5Hex), 0.87 (m, 42H, H-6Hex);
13C NMR (125.7 MHz, DMSO-d6,
313 K): d = 184.2, 183.2 (CS), 172.9, 171.9 (CO ester), 156.3
(CO carbamate), 96.6 (C-1), 83.9 (C-1Glc), 79.1 (CMe3), 78.4
(C-4), 77.6 (C-3Glc), 77.6 (C-5Glc), 73.1 (C-2Glc), 73.0 (C-6), 72.2
(C-4Glc), 71.6 (C-5), 70.6 (C-2, C-3), 44.1, 43.8, 44.3 (CH2NHCS),
42.4 (C-6Glc), 33.9, 33.7 (C-2Hex), 33.1 (CH2NCyst), 31.3, 31.1
(C-4Hex), 28.7 (CMe3), 24.3, 24.2 (C-3Hex), 22.2 (C-5Hex), 14.0
(C-6Hex); ESIMS: m/z 2979.7 [M + 2K]
2+; anal. calcd for
C245H427N35O84S21: C, 50.04; H, 7.32; N, 8.34. Found: C,
49.89; H, 7.22; N, 8.18.
Heptakis[2,3-di-O-hexanoyl-6-[2-[N0[-2-[N0-(6-amino-6-deoxy-b-D-
glucopyranosyl)thioureido]ethyl]thioureido]ethylthio]]cyclomalto-
heptaose heptahydrochloride (2). Compound 18 (46 mg, 7.8 mmol)
was treated with TFA–DCM (1 : 1, 2 mL) at rt for 2 h. Then,
solvent was evaporated and acid traces were removed by
co-evaporation with water, and the residue was freeze-dried from
diluted HCl. Yield: 37 mg (93%); [a]D = +426.5 (c 0.75, MeOH);
1H NMR (500 MHz, 5 : 1 CD3OD–D2O, 333 K): d = 5.40 (m, 7H,
H-1Glc), 5.33 (t, 7H, J2,3 = J3,4 = 9.0 Hz, H-3), 5.19 (d, 7H, J1,2 = 3.6 Hz,
H-1), 4.86 (dd, 7H, J1,2 = 4.0 Hz, H-2), 4.20 (m, 7H, H-5), 3.94
(t, 7H, J4,5 = 9.0 Hz, H-4), 3.70 (m, 7H, H-5Glc), 3.74 (bs, 42H,
2 CH2NHCS, CH2NCyst), 3.56 (t, 7H, J2,3 = J3,4 = 9.0 Hz, H-3Glc),
3.51 (m, 7H, H-2Glc), 3.46 (ddd, 7H, J6a,6b = 14 Hz, J5,6a = 2.8 Hz,
H-6aGlc), 3.31 (m, 7H, H-4Glc), 3.18 (m, 14H, H-6a, H6b), 3.09
(dd, 7H, J5,6b = 8.8 Hz, H-6bGlc), 2.97 (bs, 14H, CH2SCys), 2.45–2.28
(m, 28H, CH2CO), 1.66 (m, 28H, CH2CH2CO), 1.37 (m, 56H,
CH2CH3, CH2CH2CH3), 0.95 (m, 42H, CH3);
13C NMR (125.7
MHz, DMSO-d6, 323 K): d = 186.4, 185.7 (CS), 175.6, 174.5 (CO
ester), 99.3 (C-1), 86.5 (C-1Glc), 80.1 (C-4), 75.4 (C-3Glc), 74.5
(C-5Glc), 74.6 (C-6, C-2Glc, C-4Glc), 74.2 (C-5), 73.3 (C-2, C-3), 48.9
(C-6Glc), 46.8, 46.5, 46.1 (CH2NHCS, CH2NCyst), 36.5, 36.4, 35.7
(C-2Hex), 33.9, 33.8 (C.4Hex), 32.0 (CH2SCyst), 27.0, 26.9 (C-3Hex),
24.9 (C-5Hex), 16.7 (C-6Hex); ESIMS: m/z 1727.1 [M + 3H]
3+; anal.
calcd for C210H378N35O70S21: C, 46.41; H, 7.01; N, 9.02. Found: C,
46.29; H, 6.88; N, 8.87.
NJC Paper
 
View Article Online
5222 | New J. Chem., 2014, 38, 5215--5225 This journal is©The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2014
Heptakis[2,3-di-O-hexanoyl-6-[2-[N0[-2-[N0-(3,6-dideoxy-3,6-di-
tert-butoxycarbonylamino-b-D-glucopyranosyl)thioureido]ethyl]
thioureido]ethylthio]]cyclomaltoheptaose (19). To a solution of
1733 (86 mg, 26.7 mmol) in DCM (1 mL), Et3N (23 mL, 0.17 mmol,
1.1 eq.) and 15 (78 mg, 0.206 mmol, 1.1 eq.) in DMF (3 mL)
were added and the reaction mixture was stirred at rt for 11 days,
then concentrated. The solvent was removed under vacuum and
the residue purified by column chromatography 70 : 10 : 1 -
70 : 20 : 1 DCM–MeOH–H2O to give 19 as an amorphous solid.
Yield: 91 mg (52%); Rf = 0.50 (70 : 10 : 1 DCM–MeOH–H2O); [a]D =
+494 (c 1.0, MeOH); UV (MeOH): 285, 250 nm (emM 50.5, 106.9);
IR (KBr): nmax = 3325, 2957, 2930, 2856, 1749, 1698, 150, 1167,
1040 cm1; 1H NMR (500 MHz, CD3OD, 333 K): d = 5.46 (d, 7H,
J1,2 = 9.5 Hz, H-1Glc), 5.36 (bs, 7H, H-3), 5.19 (bs, 7H, H-1), 4.86
(bs, 7H, H-2), 4.57 (t, 14H, 3JH,H = 7.5 Hz, CH2NHCS), 4.25
(m, 7H, H-5), 3.96 (bs, 7H, H-4), 3.96 (t, 14H, 3JH,H = 7.8 Hz,
CH2NCyst), 3.58 (dd, 7H, J6a,6b = 14.0 Hz, J5,6a = 2.0 Hz, H-6aGlc),
3.56 (m, 28H, CH2NHCS, CH2SCyst), 3.52 (t, 7H, J2,3 = 9.5 Hz,
H-2Glc), 3.46 (t, 7H, J3,4 = 9.5 Hz, H-3Glc), 3.41 (ddd, 7H, J4,5 =
9.5 Hz, J5,6b = 7.5 Hz, H-5Glc), 3.29 (t, 7H, H-4Glc), 3.28 (m, 14H,
H-6a, H6b), 3.17 (dd, 7H, H-6bGlc), 2.52–2.24 (m, 28H, H-2Hex),
1.66 (m, 28H, H-3Hex), 1.47, 1.46 (2 s, 63H each, 2 CMe3), 1.42–
1.30 (m, 56H, H-4Hex, H-5Hex), 0.96 (m, 42H, H-6Hex);
13C NMR
(125.7 MHz, CD3OD, 333 K): d = 185.5, 181.5 (CS), 175.9, 174.7
(CO ester), 160.4, 159.8 (2 CO carbamate), 99.4 (C-1), 88.5
(C-1Glc), 81.8 (CMe3), 80.6 (C-4, C-5Glc), 74.2 (C-5), 73.9 (C-2Glc),
73.0 (C-6, C-2, C-3) 72.7 (C-4Glc), 63.3 (C-3Glc), 54.6 (CH2NHCS),
53.9 (CH2NCyst), 44.5 (C-6Glc), 42.4 (CH2NHCS), 36.4, 36.3 (C-2Hex),
35.2 (CH2SCyst), 33.8, 33.7 (C-4Hex), 30.0 (CMe3), 26.8 (C-3Hex), 24.6
(C-5Hex), 15.6, 15.5 (C-6Hex); anal. calcd for C280H490N42O981S21: C,
51.15; H, 7.51; N, 8.95. Found: C, 50.87; H, 7.29; N, 8.71.
Heptakis[2,3-di-O-hexanoyl-6-[2-[N 0[-2-[N0-(3,6-diamino-3,6-
dideoxy-b-D-glucopyranosyl)thioureido]ethyl]thioureido]ethyl-
thio]]cyclomaltoheptaose tetradecahydrochloride (3). Com-
pound 19 (81 mg, 13.8 mmol) was treated with TFA–DCM
(1 : 1, 2 mL) at rt for 4 h. Then, solvent was evaporated and
acid traces were removed by co-evaporation with water, and
the residue was dissolved in 10 mM HCl and freeze-dried to
yield the unprotected compound 3. Yield: 78 mg (quantita-
tive); [a]D = +470.6 (c 1.0, MeOH); UV (MeOH): 247, 270 nm
(emM 62.8, 35.5); IR (KBr): nmax = 2959, 1789, 1747, 1676, 1286,
1039 cm1; 1H NMR (500 MHz, CD3OD, 333 K): d = 5.46 (d, 7H,
J1,2 = 8.3 Hz H-1Glc), 5.35 (bs, 7H, H-3), 5.18 (bs, 7H, H-1), 4.84
(bs, 7H, H-2), 4.56 (m, 14H, CH2NHCS), 4.23 (bs, 7H, H-5),
4.00 (t, 14H, 3JH,H = 7.3 Hz, CH2NCyst), 3.77 (dd, 7H, J2,3 = 9.8 Hz,
H-2Glc), 3.76 (m, 14H, H-5Glc), 3.61 (t, 7H, J2,3 = J3,4 = 9.1 Hz,
H-3Glc), 3.58 (t, 28H,
3JH,H = 7.3 Hz, CH2NHCS, CH2SCys), 3.47
(dd, 7H, J6a,6b = 13.6 Hz, J5,6a = 3.1 Hz, H-6aGlc), 3.25 (m, 14H,
H-6a, H6b), 3.17 (t, 7H, J4,5 = 9.1 Hz, H-4Glc), 3.11 (dd, 7H, J5,6b =
8.8 Hz, H-6bGlc), 2.43–2.29 (m, 28H, H-2Hex), 1.64 (m, 28H, H-
3Hex), 1.36 (m, 56H, H-5Hex, H-4Hex), 0.94 (m, 42H, H-6Hex);
13C
NMR (125.7 MHz, CD3OD, 323 K): d = 185.9 (CS), 176.0, 174.8
(CO ester), 99.4 (C-1), 88.3 (C-1Glc), 86.1 (C-4), 81.6 (C-5Glc), 77.5
(C-5), 76.0–68.7 (C-6, C-4Glc, C-2, C-3), 63.1 (C-2Glc), 61.9 (C-3Glc),
54.7 (CH2NCyst), 49.4 (C-6Glc), 45.4, 43.2, 42.5 (CH2NHCS), 36.5,
36.4 (C-2Hex), 33.7 (C.4Hex), 31.9 (CH2SCyst), 26.8 (C-3Hex), 24.7
(C-5Hex), 15.5 (C-6Hex); anal. calcd for C210H392N42O70S21: C,
44.38; H, 6.95; N, 10.35. Found: C, 44.01; H, 6.62; N, 9.97;
S, 11.49.
Heptakis[2,3-di-O-hexanoyl-6-[2-[N0[-2-[N0-(3-deoxy-3-tert-butoxy-
carbonylamino-b-D-glucopyranosyl)thioureido]ethyl]-thioureido]-
ethylthio]]cyclomaltoheptaose (20). To a solution of 1733 (32 mg,
9.9 mmol) in DMF (1.3 mL) a solution of Et3N (9.5 mL, 69 mmol,
1 eq.) and 16 (29 mg, 76 mmol, 1.1 eq.) in DMF (1.5 mL) were
added and the reaction mixture was stirred at rt for 7 days, then
concentrated. The solvent was removed under vacuum and the
residue was purified by column chromatography 70 : 20 : 1 -
70 : 10 : 1 DCM–MeOH–H2O, to give 20. Yield: 37 mg (64%);
Rf = 0.53 (70 : 20 : 1 DCM–MeOH–H2O); [a]D = +59.0 (c 1.0,
DCM); UV (DCM): 247 nm (emM 206.1); IR (NaCl): nmax = 3319,
2957, 1750, 1693, 1247, 1165, 1038 cm1; 1H NMR (500 MHz,
CD3OD, 323 K): d = 5.31 (bt, 7H, H-3), 5.26 (bs, 7H, H-1Glc), 5.17
(d, 7H, J1,2 = 3.0 Hz, H-1), 4.84 (m, 7H, H-2), 4.18 (m, 7H, H-5),
3.90 (t, 7H, J4,5 = 8.5 Hz, H-4), 3.89 (bd, 7H, J6a,6b = 12.5 Hz,
H-6aGlc), 3.76 (bs, 42H, 2 CH2NHCS, CH2NCyst), 3.73 (m, 7H,
H-6bGlc), 3.53–3.40 (m, 28H, H-5Glc, H-3Glc, H-2Glc, H-4Glc), 3.28
(m, 7H, H-6a), 3.17 (m, 7H, H6b), 2.93 (bs, 14H, CH2SCys), 2.42
(m, 14H, H-2Hex), 2.33 (m, 7H, H-2aHex), 2.25 (m, 7H, H-2bHex),
1.63 (m, 28H, H-3Hex), 1.45 (s, 63H, CMe3), 1.32 (m, 56H, H-5Hex,
H-3Hex), 0.89 (m, 42H, H-6Hex);
13C NMR (125.7 MHz, CD3OD,
323 K): d = 183.9, 182.7 (CS), 173.4, 172.1 (CO ester), 157.8 (CO
carbamate), 96.8 (C-1), 84.6 (C-1Glc), 79.5 (CMe3), 79.3 (C-4Glc‡),
79.0 (C-4, C-5Glc‡), 71.9 (C-5), 71.1 (C-3), 70.6 (C-2), 68.5 (C-2Glc),
61.3 (C-6Glc), 60.5 (C-3Glc), 45.0, 44.0 (CH2NHCS, CH2NCyst), 33.8,
33.7 (C-6, C-2Hex), 32.7 (CH2SCyst), 31.2, 31.1 (C-4Hex), 27.6
(C-3Hex), 24.2 (CMe3), 22.1 (C-5Hex), 13.1 (C-6Hex). Anal. calcd for
C245H427N35O84S21: C, 50.04; H, 7.32; N, 8.34, S, 11.45. Found: C,
49.78; H, 6.98; N, 8.01; S, 11.03.
Heptakis[2,3-di-O-hexanoyl-6-[2-[N0[-2-[N0-(3-amino-3-deoxy-b-D-
glucopyranosyl)thioureido]ethyl]thioureido]ethylthio]]cyclomalto-
heptaose heptahydrochloride (4). Compound 20 (36 mg,
5.5 mmol) was treated with TFA–DCM (1 : 1, 2 mL) at rt for 4 h.
Then, solvent was evaporated and acid traces were removed by
co-evaporation with water, and the residue was dissolved in
10 mM HCl and freeze-dried to yield the unprotected com-
pound 4. Yield: 30 mg (quantitative); [a]D = +27.8 (c 1.0, MeOH);
UV (MeOH): 339 nm (emM 1.1); IR (KBr): nmax = 3288, 2959, 1760,
1667, 1035 cm1; 1H NMR (500 MHz, CD3OD, 333 K): d = 5.44
(m, 7H, H-1Glc), 5.31 (bs, 7H, H-3), 5.16 (bs, 7H, H-1), 4.83 (bs, 7H,
H-2), 4.18 (m, 7H, H-5), 3.90 (m, 7H, H-4), 3.88 (bd, 7H, J6a,6b =
11.5 Hz, H-6aGlc), 3.77 (bs, 42H, 2 CH2NHCS, CH2NCyst), 3.72–3.59
(m, 21H, H-2Glc, H-4Glc, H-6bGlc), 3.53 (m, 7H, H-5Glc), 3.27 (m,
7H, H-6a), 3.17 (m, 14H, H-6b, H-3Glc), 2.96 (bs, 14H, CH2SCys),
2.42–2.24 (m, 28H, H-2Hex), 1.63 (m, 28H, H-3Hex), 1.37–1.28 (m,
56H, H-5Hex, H-4Hex), 0.91 (m, 42H, H-6Hex);
13C NMR (125.7MHz,
CD3OD, 333 K): d = 185.6, 183.4 (CS), 174.7, 173.4 (CO ester), 98.2
(C-1), 85.6 (C-1Glc), 80.0 (C-5Glc, C-4), 73.2 (C-5), 71.9 (C-3), 71.6
(C-2), 70.3 (C-4Glc), 67.6 (C-2Glc), 61.9 (C-6Glc), 61.0 (C-3Glc), 45.4,
45.0, 44.3 (CH2NHCS, CH2NCyst), 35.1, 35.0 (C-6, C-2Hex), 34.0
(CH2SCyst), 32.5, 32.4 (C-4Hex), 25.5 (C-3Hex), 23.4 (C-5Hex), 14.4,
‡ Assignment of the signal can be exchanged.
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14.3 (C-6Hex). Anal. calcd for C210H378N35O70S21: C, 46.41; H, 7.01;
N, 9.02; S, 12.39. Found: C, 46.07; H, 6.73; N, 8.76; S, 12.10.
Preparation of nanocomplexes composed of pGaCD 2–4 and
pDNA (pTG11236)
The plasmid pTG11236 (pCMV-SV40-luciferase-SV40pA), used
for the preparation of the pDNA complexes and for transfection
assay, is a plasmid of 5739 bp (base pairs). The quantities of
compound used were calculated according to the desired pDNA
concentration of 0.1 mg mL1 (303 mM phosphate), the N/P
ratio, the molar weight and the number of protonable nitrogens
in the selected CD derivative or Jet-PEI.47,48 Experiments were
performed for N/P 5 and 10. Concerning the preparation of the
DNA complexes from CD derivatives and Jet-PEI, pDNA was
diluted in HEPES (20 mM, pH 7.4) to a final concentration of
303 mM, and then the desired amount of CD derivative was
added from 10 or 20 mM stock solution (DMSO). For Jet-PEI
polyplexes, pDNA was diluted in a 150 mM NaCl solution to a
final phosphate concentration of 303 mM, and then the desired
amount of Jet-PEI was added from a 7.5 mMwater solution. The
preparation was vortexed for 2 h and used for characterization
or transfection experiments.
Agarose gel electrophoresis
Each CD derivative/pDNA formulation (20 mL, 0.4 mg of plasmid)
was submitted to electrophoresis for about 30 min under 150 V
through a 0.8% agarose gel in TAE 1 (Tris-acetate–EDTA) buffer
and stained by spreading a solution of ethidium bromide (EtBr,
Sigma) in TAE buffer (20 mL of EtBr in a 10 mg mL1 solution of
200 mL of TAE). The DNA was then visualized after photograph-
ing on an UV transilluminator. The plasmid integrity in each
sample was confirmed by electrophoresis after decomplexation
with sodium dodecyl sulfate (SDS, 8%).
Measurement of CDplex size and of the n-potential by dynamic
light scattering (DLS)
The average size of the glycoCDplexes was measured using a
Zetasizer Nano (Malvern Instruments, Paris, France) with the
following specification: sampling time, automatic; number of
measurements, 3 per sample; medium viscosity, 1.054 cP;
refractive index, 1.33; scattering angle, 1731; l = 633 nm;
temperature, 25 1C. Data were analyzed using the multimodal
number distribution software included in the instrument.
Results are given as volume distribution of the major popula-
tion by the mean diameter with its standard deviation. Zeta
potential measurements on the glycoCDplexes were made with
the same apparatus using ‘‘Mixed Mode Measurement’’ phase
analysis light scattering (M3-PALS).
M3 consists of both slow field reversal and fast field reversal
measurements, hence the name ‘Mixed Mode Measurement’ that
improves accuracy and resolution. The following specifications
were applied: sampling time, automatic; number of measurements,
3 per sample; medium viscosity, 1.054 cP; medium dielectric
constant, 80; temperature, 25 1C.
Before each series of experiments, the performance of the
instruments was checked with either 90 nmmonodisperse latex
beads (Coulter) for DLS or with DTS 50 standard solution
(Malvern) for zeta potentials.
Transmission electron microscopy (TEM)
Formvar-carbon coated grids previously made hydrophilic by
glow discharge were placed on top of small drops of the CDplex
samples (HEPES 20 mM, pH 7.4, pDNA 303 mM phosphate)
prepared as described above. After 1–3 min of contact, grids
were negatively stained with a few drops of 1% aqueous
solution of uranyl acetate. The grids were then dried and
observed using a Philips CM12 electron microscope working
under standard conditions. All these experiments were repro-
duced twice on each formulation.
Cell-based assays
Twenty-four hours before transfection, COS-7 cells were grown
at a density of 2  104 cells per well in a 96-well plates in
Dulbecco’s modified Eagle culture medium (DMEM; Gibco-
BRL) containing 10% foetal calf serum (FCS; Sigma) and
100 units per mg penicillin and 100 mg mL1 streptomycin in
a wet (37 1C) and 5% CO2/95% air atmosphere. The above
described CDplexes and Jet-PEI:pDNA polyplexes were diluted
to 100 mL in DMEM or in DMEM supplemented with 10% FCS
in order to have 0.5 mg of pDNA in the well (15 mM phosphate).
The culture medium was removed and replaced by 100 mL of
these complexes. After 4 h and 24 h, 50 and 100 mL of DMEM
supplemented with 30% and 10% FCS, respectively, were
added. After 48 h, the transfection was stopped, the culture
medium was discarded, and the cells washed twice with 100 mL
of PBS and lysed with 50 mL of lysis buﬀer (Promega, Charbon-
nie`res, France). The lysates were frozen at 32 1C, before the
analysis of luciferase activity. This measurement was performed
on a luminometer (GENIOS PRO, Tecan France S.A) in dynamic
mode, for 10 s on 20 mL on the lysis mixture and using the
‘‘luciferase’’ determination system (Promega) in 96-well plates.
The total protein concentration per well was determined by the
BCA test (Pierce, Montluçon, France). Luciferase activity was
calculated as femtograms (fg) of luciferase per mg of protein.
The percentage of cell viability was calculated as the ratio of the
total protein amount per well of the transfected cells relative to
that measured for untreated cells  100. The data were calculated
from three or four repetitions in two fully independent experi-
ments (formulation and transfection).
Statistical analysis
Statistical tests were performed using STATGRAPHICS Plus 5.0
software. Analysis of variance (Anova) was run on the logarith-
mic transformation of transfection levels (Log 10 [fg luciferase/
mg protein]) and on the cell viability to fit normal distributions
of the data. Two factors, i.e. the nature of the complexing agent
(the CD derivative and Jet-PEI) and the N/P ratio, were analyzed
as sources of the variation of logarithmic transformation of the
transfection levels and of cell variability percentages using a
multiple comparison procedure. Tukey’s honestly significant
diﬀerence (HSD) method was used to discriminate between the
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means of cell viability percentages and the logarithmic trans-
formation of luciferase expression levels.
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